Biologic Therapy Is Associated With Improved Oncologic Outcomes in Crohn's Disease-Associated Colorectal Cancer

Area of Science:

• Gastroenterology and Oncology
• Inflammatory Bowel Disease Research
• Colorectal Cancer Etiology

Background:

• Crohn's disease patients have increased colorectal cancer (CRC) risk due to chronic inflammation.
• Biologic therapy is a primary treatment for Crohn's disease.
• The effect of biologic therapy on CRC outcomes in Crohn's patients is not well understood.

Purpose of the Study:

• To examine the association between prior biologic treatment exposure and CRC outcomes in Crohn's disease patients.
• To determine if biologic therapy influences survival and recurrence rates in Crohn's-associated CRC.

Main Methods:

• Retrospective cohort study involving adult Crohn's disease patients with CRC who had curative surgery (1998-2020).
• Analysis of exposure to biologic medications prior to cancer diagnosis.
• Evaluation of survival and recurrence outcomes.

Main Results:

• Biologic exposure was linked to a higher incidence of rectal cancer and well-to-moderately differentiated tumors.
• Patients exposed to biologics demonstrated a significantly higher 5-year disease-free survival rate (80% vs. 45%).
• Overall survival and recurrence rates showed non-significant numerical differences between groups.

Conclusions:

• Biologic therapy in Crohn's disease patients with CRC was associated with favorable tumor characteristics and significantly improved 5-year disease-free survival.
• These findings indicate that managing inflammation with biologics may impact colorectal carcinogenesis.
• Further research is warranted to elucidate the mechanisms underlying these observations.